ASH 2020 | CARTITUDE update: Patient expectations and experiences of cilta-cel in R/R myeloma
Adam Cohen, MD, Abramson Cancer Center, Philadelphia, PA, presents the findings from an analysis of patient expectations and experiences on the Phase Ib/II CARTITUDE-1 study (NCT03548207) which trialed ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory (R/R) multiple myeloma. Qualitative interviews were conducted prior to treatment with cilta-cel, a BCMA-targeted CAR T-cell therapy, as well as at the end of the post-infusion period (day 100) and during the post-treatment phase (day 184). At baseline, pain and fatigue were the most reported symptoms, the most impactful on daily life, and what patients most hoped would improve. Pain and fatigue reports both decreased in the day 100 and day 184 interviews. Patients also experienced reduced impact of myeloma on their quality of life. Expectations were mostly met or exceeded, and most patients reported a better experience with cilta-cel than previous therapies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consulting/advisory boards: Janssen, Takeda, Celgene, BMS, Oncopeptides, GlaxoSmithKline, Astrazeneca, Genentech/Roche
Research funding: Novartis, GlaxoSmithKleine
Patent royalties: Novartis
